TPC1 deficiency or blockade augments systemic anaphylaxis and mast cell activity
Elisabeth Arlt, Marco Fraticelli, Volodymyr Tsvilovskyy, Wiebke Nadolni, Andreas Breit, Thomas J. O’Neill, Stefanie Resenberger, Gunther Wennemuth, Christian Wahl‐Schott, Martin Biel, Christian Grimm, Marc Freichel, Thomas Gudermann, Norbert Klugbauer, Ingrid Boekhoff, Susanna Zierler
Abstract
Significance The worldwide prevalence of allergic and anaphylactic reactions has increased massively over recent decades. Mast cells and basophils are essential drivers of these diseases, releasing inflammatory mediators such as histamine. Here, we link the endolysosomal two-pore channel TPC1 to systemic anaphylaxis in vivo and underlying mast cell function ex vivo. TPC1-deficient mice develop enhanced systemic anaphylaxis reflected by a drop in body temperature and slower recovery compared to wild-type animals. Genetic deletion or pharmacological inhibition of TPC1 enhances mast cell degranulation and histamine release due to accelerated calcium release, mainly from the endoplasmic reticulum. Accordingly, it is tempting to speculate that activation of TPC1 ameliorates mast cell degranulation, highlighting TPC1 as a potential drug target against allergic hypersensitivity.